国药现代: 2024年年度股东大会会议资料

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. is focusing on optimizing governance, enhancing operational efficiency, and maintaining shareholder value amidst a challenging market environment, as evidenced by its financial performance and strategic initiatives [5][10][31]. Meeting Overview - The annual shareholder meeting is scheduled for June 26, 2025, at the company's headquarters in Shanghai [1][3]. - The meeting will include the reading of meeting guidelines, discussion of proposals, and voting by shareholders [4][10]. Financial Performance - In 2024, the company achieved a revenue of 10.938 billion yuan, a decrease of 9.38% year-on-year, while net profit rose to 1.084 billion yuan, an increase of 56.62% [18][21]. - The basic earnings per share increased to 0.8080 yuan, reflecting a growth of 48.72% compared to the previous year [21][31]. - The company reported a total profit of 1.673 billion yuan, up 52.57% year-on-year [22][24]. Operational Efficiency - The company has implemented measures to enhance operational efficiency, resulting in a reduction of total expenses by 28.82% year-on-year [22][23]. - The gross profit margin improved to 39.24%, while the net profit margin increased to 12.18% [26][27]. Strategic Initiatives - The company is focusing on innovation and optimizing its product portfolio, with 31 new research projects initiated and 59 product registrations completed [6][10]. - A significant emphasis is placed on enhancing investor relations and maintaining transparency in financial disclosures, achieving an A-level rating in information disclosure for three consecutive years [8][9]. Future Outlook - The company plans to continue its strategic focus on high-quality development and resource optimization, aiming to enhance its competitive edge in the pharmaceutical industry [10][30]. - The 2025 revenue forecast anticipates a growth of 3.68%, with a focus on cost control and marketing efficiency [29][30].